203 related articles for article (PubMed ID: 32188095)
41. Proliferative, pro-inflammatory, and angiogenesis regulator gene expression profile defines prognosis in different histopathological subtypes of nodal peripheral T-cell lymphoma.
de Pádua Covas Lage LA; Levy D; Xavier FD; Reis DC; de Oliveira Costa R; Gonçalves MC; Rocha V; Zerbini MCN; Pereira J
Oncotarget; 2019 Aug; 10(50):5136-5151. PubMed ID: 31497245
[TBL] [Abstract][Full Text] [Related]
42. Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma.
Crescenzo R; Abate F; Lasorsa E; Tabbo' F; Gaudiano M; Chiesa N; Di Giacomo F; Spaccarotella E; Barbarossa L; Ercole E; Todaro M; Boi M; Acquaviva A; Ficarra E; Novero D; Rinaldi A; Tousseyn T; Rosenwald A; Kenner L; Cerroni L; Tzankov A; Ponzoni M; Paulli M; Weisenburger D; Chan WC; Iqbal J; Piris MA; Zamo' A; Ciardullo C; Rossi D; Gaidano G; Pileri S; Tiacci E; Falini B; Shultz LD; Mevellec L; Vialard JE; Piva R; Bertoni F; Rabadan R; Inghirami G;
Cancer Cell; 2015 Apr; 27(4):516-32. PubMed ID: 25873174
[TBL] [Abstract][Full Text] [Related]
43. Overlap at the molecular and immunohistochemical levels between angioimmunoblastic T-cell lymphoma and a subgroup of peripheral T-cell lymphomas without specific morphological features.
Manso R; González-Rincón J; Rodríguez-Justo M; Roncador G; Gómez S; Sánchez-Beato M; Piris MA; Rodríguez-Pinilla SM
Oncotarget; 2018 Mar; 9(22):16124-16133. PubMed ID: 29662631
[TBL] [Abstract][Full Text] [Related]
44. Aggressive T-cell lymphomas: 2021 Updates on diagnosis, risk stratification and management.
Zain JM; Hanona P
Am J Hematol; 2021 Aug; 96(8):1027-1046. PubMed ID: 34111312
[TBL] [Abstract][Full Text] [Related]
45. Differential expression of cyclin D3 in ALK+ and ALK- anaplastic large cell lymphoma.
Dalton RR; Rassidakis GZ; Atwell C; Wang S; Oyarzo MP; Medeiros LJ
Hum Pathol; 2005 Jul; 36(7):806-11. PubMed ID: 16084951
[TBL] [Abstract][Full Text] [Related]
46. Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma.
Heavican TB; Bouska A; Yu J; Lone W; Amador C; Gong Q; Zhang W; Li Y; Dave BJ; Nairismägi ML; Greiner TC; Vose J; Weisenburger DD; Lachel C; Wang C; Fu K; Stevens JM; Lim ST; Ong CK; Gascoyne RD; Missiaglia E; Lemonnier F; Haioun C; Hartmann S; Pedersen MB; Laginestra MA; Wilcox RA; Teh BT; Yoshida N; Ohshima K; Seto M; Rosenwald A; Ott G; Campo E; Rimsza LM; Jaffe ES; Braziel RM; d'Amore F; Inghirami G; Bertoni F; de Leval L; Gaulard P; Staudt LM; McKeithan TW; Pileri S; Chan WC; Iqbal J
Blood; 2019 Apr; 133(15):1664-1676. PubMed ID: 30782609
[TBL] [Abstract][Full Text] [Related]
47. Linkage of expression of chemokine receptors (CXCR3 and CCR4) and cytotoxic molecules in peripheral T cell lymphoma, not otherwise specified and ALK-negative anaplastic large cell lymphoma.
Asano N; Suzuki R; Ohshima K; Kagami Y; Ishida F; Yoshino T; Ogawa H; Morishima Y; Nakamura S
Int J Hematol; 2010 Apr; 91(3):426-35. PubMed ID: 20217288
[TBL] [Abstract][Full Text] [Related]
48. [Expressions and clinical significance of GAS1, IL-1RAP and PRF1 in patients with ALK positive anaplastic large cell lymphoma].
Jiang Y; Cao D; Xu CG
Zhonghua Xue Ye Xue Za Zhi; 2018 Feb; 39(2):116-121. PubMed ID: 29562445
[No Abstract] [Full Text] [Related]
49. Oncogenic role of miR-155 in anaplastic large cell lymphoma lacking the t(2;5) translocation.
Merkel O; Hamacher F; Griessl R; Grabner L; Schiefer AI; Prutsch N; Baer C; Egger G; Schlederer M; Krenn PW; Hartmann TN; Simonitsch-Klupp I; Plass C; Staber PB; Moriggl R; Turner SD; Greil R; Kenner L
J Pathol; 2015 Aug; 236(4):445-56. PubMed ID: 25820993
[TBL] [Abstract][Full Text] [Related]
50. Aggressive T-cell lymphomas: 2019 updates on diagnosis, risk stratification, and management.
Zain JM
Am J Hematol; 2019 Aug; 94(8):929-946. PubMed ID: 31119775
[TBL] [Abstract][Full Text] [Related]
51. [Analysis of mature T-cell and NK-cell lymphoma with CD30 expression based on latest WHO classification].
Feng Y; Fu J; Yan S; Ling Y; Huang Y; Cai M; Rao H
Zhonghua Bing Li Xue Za Zhi; 2014 Aug; 43(8):508-11. PubMed ID: 25346118
[TBL] [Abstract][Full Text] [Related]
52. Systemic, primary cutaneous, and breast implant-associated ALK-negative anaplastic large-cell lymphomas present similar biologic features despite distinct clinical behavior.
Gerbe A; Alame M; Dereure O; Gonzalez S; Durand L; Tempier A; De Oliveira L; Tourneret A; Costes-Martineau V; Cacheux V; Szablewski V
Virchows Arch; 2019 Aug; 475(2):163-174. PubMed ID: 30953147
[TBL] [Abstract][Full Text] [Related]
53. Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors.
Mak V; Hamm J; Chhanabhai M; Shenkier T; Klasa R; Sehn LH; Villa D; Gascoyne RD; Connors JM; Savage KJ
J Clin Oncol; 2013 Jun; 31(16):1970-6. PubMed ID: 23610113
[TBL] [Abstract][Full Text] [Related]
54. Pathological and Molecular Features of Nodal Peripheral T-Cell Lymphomas.
Satou A; Takahara T; Tsuzuki T
Diagnostics (Basel); 2022 Aug; 12(8):. PubMed ID: 36010351
[TBL] [Abstract][Full Text] [Related]
55. Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death.
Zamo A; Chiarle R; Piva R; Howes J; Fan Y; Chilosi M; Levy DE; Inghirami G
Oncogene; 2002 Feb; 21(7):1038-47. PubMed ID: 11850821
[TBL] [Abstract][Full Text] [Related]
56. Histological type distribution and expression of nm23, VEGF, TOP2A and MUM-1 in peripheral T-cell and NK-cell lymphomas in Chinese: analysis of 313 cases.
Huang W; Ma W; Qiu T; Shan L; Zeng L; Guo L; Ying J; Lv N; Feng X
Int J Clin Exp Pathol; 2018; 11(10):5086-5093. PubMed ID: 31949586
[TBL] [Abstract][Full Text] [Related]
57. Peripheral T-Cell Lymphomas: Incorporating New Developments in Diagnostics, Prognostication, and Treatment Into Clinical Practice-PART 1: PTCL-NOS, FTCL, AITL, ALCL.
Zing NPC; Fischer T; Zain J; Federico M; Rosen ST
Oncology (Williston Park); 2018 Jul; 32(7):e74-e82. PubMed ID: 30080923
[TBL] [Abstract][Full Text] [Related]
58. Differential expression of thymus and activation regulated chemokine and its receptor CCR4 in nodal and cutaneous anaplastic large-cell lymphomas and Hodgkin's disease.
Vermeer MH; Dukers DF; ten Berge RL; Bloemena E; Wu L; Vos W; de Vries E; Tensen CP; Meijer CJ; Willemze R
Mod Pathol; 2002 Aug; 15(8):838-44. PubMed ID: 12181269
[TBL] [Abstract][Full Text] [Related]
59. MUC1 (EMA) is preferentially expressed by ALK positive anaplastic large cell lymphoma, in the normally glycosylated or only partly hypoglycosylated form.
ten Berge RL; Snijdewint FG; von Mensdorff-Pouilly S; Poort-Keesom RJ; Oudejans JJ; Meijer JW; Willemze R; Hilgers J; Meijer CJ
J Clin Pathol; 2001 Dec; 54(12):933-9. PubMed ID: 11729213
[TBL] [Abstract][Full Text] [Related]
60. Anaplastic Large Cell Lymphoma.
Medeiros LJ; Elenitoba-Johnson KS
Am J Clin Pathol; 2007 May; 127(5):707-22. PubMed ID: 17511113
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
